Patterns in blood pressure medication use in US incident dialysis patients over the first 6?months

详细信息    查看全文

• 作者：Wendy L St Peter (1) (2)
  Stephen M Sozio (3) (4)
  Tariq Shafi (3) (4)
  Patti L Ephraim (4) (5)
  Jason Luly (6)
  Aidan McDermott (7)
  Karen Bandeen-Roche (7)
  Klemens B Meyer (8)
  Deidra C Crews (3) (4)
  Julia J Scialla (9)
  Dana C Miskulin (8)
  Navdeep Tangri (10)
  Bernard G Jaar (11) (3) (4) (5)
  Wieneke M Michels (12) (4) (6)
  Albert W Wu (13) (14) (15) (5)
  L Ebony Boulware (4) (5) (6)
  
• 关键词：Blood pressure medication ; Dialysis ; Medication use patterns
• 刊名：BMC Nephrology
• 出版年：2013
• 出版时间：December 2013
• 年：2013
• 卷：14
• 期：1
• 全文大小：253 KB
• 参考文献：1. U.S. Renal Data System: / USRDS 2012 Annual Data Report: Atlas of Chronic Kidney Disease & End-Stage Renal Disease in the United States. 2012 edition. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2012.
  2. Agarwal R, Sinha AD: Cardiovascular protection with antihypertensive drugs in dialysis patients: systematic review and meta-analysis. / Hypertension 2009, 53:860-66. CrossRef
  3. Heerspink HJ, Ninomiya T, Zoungas S, / et al.: Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials. / Lancet 2009, 373:1009-015. CrossRef
  4. Iseki K, Shoji T, Nakai S, Watanabe Y, Akiba T, Tsubakihara Y: Higher survival rates of chronic hemodialysis patients on anti-hypertensive drugs. / Nephron Clin Pract 2009, 113:c183-c190. CrossRef
  5. Nakao K, Makino H, Morita S, / et al.: Beta-blocker prescription and outcomes in hemodialysis patients from the Japan Dialysis Outcomes and Practice Patterns Study. / Nephron Clin Pract 2009, 113:c132-c139. CrossRef
  6. Abbott KC, Trespalacios FC, Agodoa LY, Taylor AJ, Bakris GL: beta-Blocker use in long-term dialysis patients: association with hospitalized heart failure and mortality. / Arch Intern Med 2004, 164:2465-471. CrossRef
  7. Lopes AA, Bragg-Gresham JL, Ramirez SP, / et al.: Prescription of antihypertensive agents to haemodialysis patients: time trends and associations with patient characteristics, country and survival in the DOPPS. / Nephrol Dial Transplant 2009, 24:2809-816. CrossRef
  8. Griffith TF, Chua BS, Allen AS, Klassen PS, Reddan DN, Szczech LA: Characteristics of treated hypertension in incident hemodialysis and peritoneal dialysis patients. / Am J Kidney Dis 2003, 42:1260-269. CrossRef
  9. Ishani A, Herzog CA, Collins AJ, Foley RN: Cardiac medications and their association with cardiovascular events in incident dialysis patients: cause or effect? / Kidney Int 2004, 65:1017-025. CrossRef
  10. Kestenbaum B, Gillen DL, Sherrard DJ, Seliger S, Ball A, Stehman-Breen C: Calcium channel blocker use and mortality among patients with end-stage renal disease. / Kidney Int 2002, 61:2157-164. CrossRef
  11. Foley RN, Herzog CA, Collins AJ: Blood pressure and long-term mortality in United States hemodialysis patients: USRDS Waves 3 and 4 Study. / Kidney Int 2002, 62:1784-790. CrossRef
  12. Manley HJ, Garvin CG, Drayer DK, / et al.: Medication prescribing patterns in ambulatory haemodialysis patients: comparisons of USRDS to a large not-for-profit dialysis provider. / Nephrol Dial Transplant 2004, 19:1842-848. CrossRef
  13. Rahman M, Griffin V: Patterns of antihypertensive medication use in hemodialysis patients. / Am J Health Syst Pharm 2004, 61:1473-478.
  14. Wetmore JB, Mahnken JD, Mukhopadhyay P, / et al.: Geographic variation in cardioprotective antihypertensive medication usage in dialysis patients. / Am J Kidney Dis 2011, 58:73-3. CrossRef
  15. Frankenfield DL, Weinhandl ED, Powers CA, Howell BL, Herzog CA, St.Peter WL: Utilization and costs of cardiovascular disease medications in dialysis patients in Medicare Part D. / Am J Kidney Dis 2012, 59:670-81. CrossRef
  16. Sood MM, Battistella M, Lok CE: Patterns of cardioprotective medication prescription in incident hemodialysis patients. / Int Urol Nephrol 2009, 41:1021-027. CrossRef
  17. Boulware EL, Tangri N, Ephraim PL, / et al.: Comparative effectiveness studies to improve clinical outcomes in end stage renal disease: the DEcIDE patient outcomes in end stage renal disease study. / BMC Nephrol 2012, 13:167. CrossRef
  18. Thomas J, Teitelbaum I: Preservation of residual renal function in dialysis patients. / Adv Perit Dial 2011, 27:112-17.
  19. Jansen MA, Hart AA, Korevaar JC, Dekker FW, Boeschoten EW, Krediet RT: Predictors of the rate of decline of residual renal function in incident dialysis patients. / Kidney Int 2002, 62:1046-053. CrossRef
  20. Medcalf JF, Harris KP, Walls J: Role of diuretics in the preservation of residual renal function in patients on continuous ambulatory peritoneal dialysis. / Kidney Int 2001, 59:1128-133. CrossRef
  21. Bragg-Gresham JL, Fissell RB, Mason NA, / et al.: Diuretic use, residual renal function, and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Pattern Study (DOPPS). / Am J Kidney Dis 2007, 49:426-31. CrossRef
  22. Cice G, Ferrara L, Di Benedetto A, / et al.: Dilated cardiomyopathy in dialysis patients–beneficial effects of carvedilol: a double-blind, placebo-controlled trial. / J Am Coll Cardiol 2001, 37:407-11. CrossRef
  23. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2369/14/249/prepub
  
• 作者单位：Wendy L St Peter (1) (2)
  Stephen M Sozio (3) (4)
  Tariq Shafi (3) (4)
  Patti L Ephraim (4) (5)
  Jason Luly (6)
  Aidan McDermott (7)
  Karen Bandeen-Roche (7)
  Klemens B Meyer (8)
  Deidra C Crews (3) (4)
  Julia J Scialla (9)
  Dana C Miskulin (8)
  Navdeep Tangri (10)
  Bernard G Jaar (11) (3) (4) (5)
  Wieneke M Michels (12) (4) (6)
  Albert W Wu (13) (14) (15) (5)
  L Ebony Boulware (4) (5) (6)
  
  1. University of Minnesota College of Pharmacy, Minneapolis, MN, USA
  2. Chronic Disease Research Group, Minneapolis Medical Research Foundation, 914 South 8th Street, Suite S4.100, Minneapolis, MN, 55404, USA
  3. Division of Nephrology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
  4. Welch Center for Prevention, Epidemiology, and Clinical Research, Johns Hopkins Medical Institutions, Baltimore, MD, USA
  5. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
  6. Division of General Internal Medicine, Johns University Hopkins School of Medicine, Baltimore, MD, USA
  7. Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
  8. Division of Nephrology, Tufts University School of Medicine, Boston, MA, USA
  9. Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA
  10. Department of Medicine, Division of Nephrology, Seven Oaks General Hospital, University of Manitoba, Winnipeg, Manitoba, Canada
  11. Nephrology Center of Maryland, Baltimore, MD, USA
  12. Division of Nephrology, Department of Medicine, Academic Medical Center, Amsterdam, The Netherlands
  13. Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
  14. Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
  15. Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA
  
• ISSN：1471-2369

文摘

Background Several observational studies have evaluated the effect of a single exposure window with blood pressure (BP) medications on outcomes in incident dialysis patients, but whether BP medication prescription patterns remain stable or a single exposure window design is adequate to evaluate effect on outcomes is unclear. Methods We described patterns of BP medication prescription over 6?months after dialysis initiation in hemodialysis and peritoneal dialysis patients, stratified by cardiovascular comorbidity, diabetes, and other patient characteristics. The cohort included 13,072 adult patients (12,159 hemodialysis, 913 peritoneal dialysis) who initiated dialysis in Dialysis Clinic, Inc., facilities January 1, 2003-June 30, 2008, and remained on the original modality for at least 6?months. We evaluated monthly patterns in BP medication prescription over 6?months and at 12 and 24?months after initiation. Results Prescription patterns varied by dialysis modality over the first 6?months; substantial proportions of patients with prescriptions for beta-blockers, renin angiotensin system agents, and dihydropyridine calcium channel blockers in month 6 no longer had prescriptions for these medications by month 24. Prescription of specific medication classes varied by comorbidity, race/ethnicity, and age, but little by sex. The mean number of medications was 2.5 at month 6 in hemodialysis and peritoneal dialysis cohorts. Conclusions This study evaluates BP medication patterns in both hemodialysis and peritoneal dialysis patients over the first 6?months of dialysis. Our findings highlight the challenges of assessing comparative effectiveness of a single BP medication class in dialysis patients. Longitudinal designs should be used to account for changes in BP medication management over time, and designs that incorporate common combinations should be considered.